All Stories

  1. Cytoreduction in MPN-SVT: Is the Association Causal?

    Article • Blood Advances, October 2026, American Society of Hematology

    Dr Ahmet Emre Eskazan

  2. When platelets reach a million: insights from hematologists

    Article • Annals of Hematology, September 2026, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  3. Revisiting the PLASMIC Score and the Future of ADAMTS13 Prediction

    Article • Blood Vessels Thrombosis & Hemostasis, June 2026, Elsevier

    Dr Ahmet Emre Eskazan

  4. Evaluation of DNA methylation-based age prediction accuracy in leukemia patients using a six-CpG model trained on healthy blood

    Article • Forensic Science Medicine and Pathology, April 2026, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  5. Pre‐procedure platelet count is not the only factor in the development of bleeding complications following lumbar puncture and central venous catheter insertion

    Article • Internal Medicine Journal, April 2026, Wiley

    Dr Ahmet Emre Eskazan

  6. Determinants of Survival in Mantle Cell Lymphoma: A 20-Year Single-Center Retrospective Analysis

    Article • Indian Journal of Hematology and Blood Transfusion, March 2026, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  7. Emerging Survival Predictor Model in Essential Thrombocythemia: The AAA + Model

    Article • American Journal of Hematology, March 2026, Wiley

    Dr Ahmet Emre Eskazan

  8. Impact of Systemic Inflammatory and Autoimmune Diseases on Outcomes in Patients with Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia

    Article • Clinical Lymphoma Myeloma & Leukemia, March 2026, Elsevier

    Dr Ahmet Emre Eskazan

  9. Precision Anticoagulation: The Imperative Usage of DOACs for Disease‐Specific Risk Stratification in MPNs and Multiple Myeloma

    Article • European Journal Of Haematology, February 2026, Wiley

    Dr Ahmet Emre Eskazan

  10. Plasma Cell Contamination in Autografts Determined by Dual Quantification Before Cryopreservation and After Thawing Predicts Transplant Outcomes in Multiple Myeloma: A Prospective, Proof-of-Concept Study

    Article • Cerrahpaşa Medical Journal, February 2026, AVES Publishing Co.

    Dr Ahmet Emre Eskazan

  11. Navigating biosimilar transitions in IV rituximab therapy: Efficacy and safety insights from a real-world switching study

    Article • Journal of Oncology Pharmacy Practice, January 2026, SAGE Publications

    Dr Ahmet Emre Eskazan

  12. Impact of Systemic Inflammatory and Autoimmune Diseases on Outcomes in Patients with Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia

    Article • January 2026, Elsevier

    Dr Ahmet Emre Eskazan

  13. Citrullinated Histone 3 as a Marker of NETosis at Opposite Ends of Hemostasis: Evidence From Thrombosis-Prone MPN and Bleeding-Prone Hemophilia

    Article • Clinical and Applied Thrombosis/Hemostasis, January 2026, SAGE Publications

    Dr Ahmet Emre Eskazan

  14. Peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia and tyrosine kinase inhibitor response: Questions remain!

    Article • Cancer, December 2025, Wiley

    Dr Ahmet Emre Eskazan

  15. Is there a best JAK inhibitor in myelofibrosis when it comes to safety and anemia outcomes?

    Article • Future Oncology, November 2025, Taylor & Francis

    Dr Ahmet Emre Eskazan

  16. STAMP inhibitors and their future in CML therapy: a critical analysis

    Article • Blood Cancer Journal, October 2025, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  17. A Practical Tool for Predicting Outcomes in Essential Thrombocythemia: Triple A Risk Model and Beyond

    Article • Blood Advances, October 2025, American Society of Hematology

    Dr Ahmet Emre Eskazan

  18. Masked polycythemia vera: diagnostic challenges and clinical implications

    Article • Expert Review of Hematology, October 2025, Taylor & Francis

    Dr Ahmet Emre Eskazan

  19. Refining the risk stratification in advanced‐stage classical Hodgkin lymphoma: A critical analysis of clinical prediction models

    Article • British Journal of Haematology, August 2025, Wiley

    Dr Ahmet Emre Eskazan

  20. Perioperative Management of Atypical Hemolytic Uremic Syndrome in a Patient on Maintenance Eculizumab Therapy: A Case Report and Review of the Literature

    Article • Nephron, May 2025, Karger Publishers

    Dr Ahmet Emre Eskazan

  21. rADAMTS13 in cTTP: a new standard of care?

    Article • Blood, May 2025, American Society of Hematology

    Dr Ahmet Emre Eskazan

  22. Comment on: “Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study” by Busque et al.

    Article • Blood Cancer Journal, April 2025, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  23. The validation of advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI) in Turkish patients with classical Hodgkin lymphoma

    Article • Annals of Hematology, March 2025, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  24. Patient‐reported outcomes in Chinese patients with chronic myeloid leukemia receiving olverembatinib: Quality of life matters!

    Article • Cancer, January 2025, Wiley

    Dr Ahmet Emre Eskazan

  25. Unusual synchronous and metachronous association of hematologic neoplasms with gynecologic neoplasms: A case series and literature review

    Article • International Journal of Gynecology & Obstetrics, December 2024, Wiley

    Dr Ahmet Emre Eskazan

  26. Complications of therapeutic plasma exchange: A retrospective, single‐center study of 2505 procedures performed in 338 patients over 15 years

    Article • Therapeutic Apheresis and Dialysis, June 2024, Wiley

    Dr Ahmet Emre Eskazan

  27. Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?

    Article • Expert Review of Hematology, June 2024, Taylor & Francis

    Dr Ahmet Emre Eskazan

  28. A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia

    Article • Expert Opinion on Drug Safety, April 2024, Taylor & Francis

    Dr Ahmet Emre Eskazan

  29. Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP

    Article • Pleura and Peritoneum, February 2024, De Gruyter

    Dr Ahmet Emre Eskazan

  30. Acute Thrombocytopenia Complicating the Initial Administration of Obinutuzumab: Is It More Frequent Than We Think?

    Article • Oncology and Therapy, January 2024, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  31. Treatment of anemia in myelofibrosis: focusing on novel therapeutic options

    Article • Expert Opinion on Investigational Drugs, December 2023, Taylor & Francis

    Dr Ahmet Emre Eskazan

  32. Does discontinuing bleomycin due to toxicity increase the risk of lymphoma progression? Real-life data from a homogeneous population of advanced stage Hodgkin lymphoma

    Article • Journal of Chemotherapy, November 2023, Taylor & Francis

    Dr Ahmet Emre Eskazan

  33. A cross-sectional study on restless legs syndrome (RLS) in polycythemia vera (PV): is iron deficiency the only culprit?

    Article • Neurological Research, September 2023, Taylor & Francis

    Dr Ahmet Emre Eskazan

  34. Flow Cytometric Analysis of Lymphocyte Subsets of Covid-19 Patients from A Single Centre in Turkey

    Article • Acıbadem Üniversitesi Sağlık Bilimleri Dergisi, September 2023, Acibadem Universitesi Saglik Bilimleri Dergisi

    Dr Ahmet Emre Eskazan

  35. Plasma exchange therapy in systemic lupus erythematosus: A single-center retrospective cohort study

    Article • Ulusal Romatoloji Dergisi, July 2023, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  36. Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults

    Article • Expert Opinion on Pharmacotherapy, July 2023, Taylor & Francis

    Dr Ahmet Emre Eskazan

  37. Fine‐tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic‐phase chronic myeloid leukemia: The choice of the right TKI for the right patient

    Article • Cancer, July 2023, Wiley

    Dr Ahmet Emre Eskazan

  38. Diagnostic and Treatment Obstacles in Acute Myeloid Leukemia: Social, Operational, and Financial

    Article • Oncology and Therapy, May 2023, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  39. Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted!

    Article • Cancer, May 2023, Wiley

    Dr Ahmet Emre Eskazan

  40. Ponatinib both as an effective bridge to allogeneic hematopoietic stem cell transplantation and as posttransplant maintenance therapy in a chronic myeloid leukemia patient with myeloid blast crisis

    Article • Hematology Transfusion and Cell Therapy, April 2023, Elsevier

    Dr Ahmet Emre Eskazan

  41. ATRA+ATO combination in APL – A commentary on “evolving of treatment paradigms and challenges in acute promyelocytic leukaemia: A real-world analysis of 1105 patients over the last three decades” by Teng-Fei et al.

    Article • Translational Oncology, March 2023, Elsevier

    Dr Ahmet Emre Eskazan

  42. Breaking the mold: asciminib as a standard-of-care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting

    Article • Future Oncology, March 2023, Taylor & Francis

    Dr Ahmet Emre Eskazan

  43. Upregulation of SPINK2 in acute myeloid leukemia

    Article • Advances in Laboratory Medicine / Avances en Medicina de Laboratorio, February 2023, De Gruyter

    Dr Ahmet Emre Eskazan

  44. Elevación de SPINK2 en leucemia mieloide aguda

    Article • Advances in Laboratory Medicine / Avances en Medicina de Laboratorio, February 2023, De Gruyter

    Dr Ahmet Emre Eskazan

  45. Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review

    Article • Expert Review of Hematology, February 2023, Taylor & Francis

    Dr Ahmet Emre Eskazan

  46. A Systematic Review on Second Treatment-Free Remission (TFR) Attempt in Chronic Myeloid Leukemia (CML): Can it be Applied in Clinical Practice?

    Article • Clinical Lymphoma Myeloma & Leukemia, January 2023, Elsevier

    Dr Ahmet Emre Eskazan

  47. Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate!

    Article • Cancer, December 2022, Wiley

    Dr Ahmet Emre Eskazan

  48. Plasma exchange therapy in ANCA-associated vasculitis: A single-center retrospective cohort study

    Article • Ulusal Romatoloji Dergisi, December 2022, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  49. Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities

    Article • International Journal of Hematology, September 2022, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  50. Recent Advances in the Therapeutic Armamentarium of Acute Myeloid Leukemia: A Focus on the 63rd American Society of Hematology Annual Meeting Abstracts

    Article • Current Pharmaceutical Design, September 2022, Bentham Science Publishers

    Dr Ahmet Emre Eskazan

  51. Dasatinib-related pleural effusion and lymphocytosis rates are different between adult and pediatric patients with Philadelphia chromosome-positive leukemias: are age and comorbidities only to blame?

    Article • Expert Review of Respiratory Medicine, August 2022, Taylor & Francis

    Dr Ahmet Emre Eskazan

  52. A Rare and Aggressive Disease: Answer

    Article • American Journal of Dermatopathology, August 2022, Wolters Kluwer Health

    Dr Ahmet Emre Eskazan

  53. A new dawn for upfront autologous SCT in NK/T‐cell lymphomas: One more step forward in reasoning

    Article • International Journal of Cancer, June 2022, Wiley

    Dr Ahmet Emre Eskazan

  54. Is it possible to predict the pCR with CBC? A commentary on “correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer” by Meng et al.

    Article • Translational Oncology, June 2022, Elsevier

    Dr Ahmet Emre Eskazan

  55. Treatment Responses, Toxicity, and Survival in Patients with Classical Hodgkin Lymphoma Aged ≥50 Years: A Single-Center Experience Over Two Decades

    Article • Cancer Management and Research, June 2022, Taylor & Francis

    Dr Ahmet Emre Eskazan

  56. Management of chronic myeloid leukemia in myeloid blastic phase with novel therapies: a systematic literature review

    Article • Expert Review of Hematology, May 2022, Taylor & Francis

    Dr Ahmet Emre Eskazan

  57. Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al.

    Article • Translational Oncology, May 2022, Elsevier

    Dr Ahmet Emre Eskazan

  58. The Effect of Comorbidities on the Choice of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia

    Article • International Journal of Hematologic Oncology, March 2022, Taylor & Francis

    Dr Ahmet Emre Eskazan

  59. Spotlight Commentary – Voxelotor: A new kid on the block in the treatment of sickle cell disease

    Article • British Journal of Clinical Pharmacology, February 2022, Wiley

    Dr Ahmet Emre Eskazan

  60. <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging Appearance of Gastrointestinal Behcet’s Disease

    Article • Molecular Imaging and Radionuclide Therapy, February 2022, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  61. Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting

    Article • Expert Review of Hematology, February 2022, Taylor & Francis

    Dr Ahmet Emre Eskazan

  62. Asciminib as a new option in the treatment of chronic myeloid leukemia

    Article • Future Oncology, November 2021, Taylor & Francis

    Dr Ahmet Emre Eskazan

  63. Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

    Article • Expert Review of Hematology, October 2021, Taylor & Francis

    Dr Ahmet Emre Eskazan

  64. Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab: COMMENT from Eşkazan et al

    Article • Journal of Thrombosis and Haemostasis, October 2021, Elsevier

    Dr Ahmet Emre Eskazan

  65. Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs

    Article • Blood Advances, September 2021, American Society of Hematology

    Dr Ahmet Emre Eskazan

  66. New kid on the block: C-reactive protein-to-albumin ratio as a new prognostic marker for chronic lymphocytic leukemia: Comment on “C-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leuka...

    Article • Translational Oncology, August 2021, Elsevier

    Dr Ahmet Emre Eskazan

  67. Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?

    Article • Expert Review of Clinical Pharmacology, July 2021, Taylor & Francis

    Dr Ahmet Emre Eskazan

  68. A clinical appraisal of chronic myeloid leukaemia (CML)‐related death and CML‐specific death—Are they synonymous?

    Article • International Journal of Clinical Practice, May 2021, Wiley

    Dr Ahmet Emre Eskazan

  69. Candida esophagitis incidentally detected by 18F‐FDG PET/CT in a patient with CNS lymphoma

    Article • Clinical Case Reports, May 2021, Wiley

    Dr Ahmet Emre Eskazan

  70. Asciminib in chronic myeloid leukemia: many questions still remain to be answered

    Article • Blood Cancer Journal, April 2021, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  71. The prognostic value of serum levels of a proliferation-inducing ligand (APRIL) in treatment-naïve patients with chronic lymphocytic leukemia

    Article • TURKISH JOURNAL OF MEDICAL SCIENCES, February 2021, The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS

    Professor Hafize Uzun, Dr Ahmet Emre Eskazan

  72. What is the best treatment approach for sporadic late‐onset nemaline myopathy associated with “monoclonal gammopathy of neurological significance”?

    Article • International Journal of Cancer, February 2021, Wiley

    Dr Ahmet Emre Eskazan

  73. Bosutinib – related pleural effusion in patients with chronic myeloid leukemia

    Article • Expert Opinion on Drug Safety, January 2021, Taylor & Francis

    Dr Ahmet Emre Eskazan

  74. Platelet count threshold for lumbar puncture: Does one size really fit all?

    Article • Transfusion, September 2020, Wiley

    Dr Ahmet Emre Eskazan

  75. Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor

    Article • Cancer Reports, September 2020, Wiley

    Dr Ahmet Emre Eskazan

  76. Copy number variations in adult patients with chronic immune thrombocytopenia

    Article • Expert Review of Hematology, September 2020, Taylor & Francis

    Dr Ahmet Emre Eskazan

  77. Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes

    Article • Journal of Blood Medicine, September 2020, Taylor & Francis

    Dr Ahmet Emre Eskazan

  78. Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?

    Article • Expert Review of Hematology, August 2020, Taylor & Francis

    Dr Ahmet Emre Eskazan

  79. COVID‐19 presenting with immune thrombocytopenia: a case report and review of the literature

    Article • Journal of Medical Virology, June 2020, Wiley

    Dr Ahmet Emre Eskazan

  80. Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID‐19 pandemic

    Article • British Journal of Clinical Pharmacology, May 2020, Wiley

    Dr Ahmet Emre Eskazan

  81. Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML

    Article • Future Oncology, May 2020, Future Medicine

    Dr Ahmet Emre Eskazan

  82. Follicular lymphoma generating in a patient with non-small cell lung cancer following nivolumab discontinuation

    Article • Journal of Oncology Pharmacy Practice, April 2020, SAGE Publications

    Dr Ahmet Emre Eskazan

  83. Chronic myeloid leukemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic

    Article • April 2020, Wiley

    Dr Ahmet Emre Eskazan

  84. Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia?

    Article • Leukemia, March 2020, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  85. Novel therapeutic approaches in chronic myeloid leukemia

    Article • Leukemia Research, February 2020, Elsevier

    Dr Ahmet Emre Eskazan

  86. Bosutinib – an effective and safe treatment option in the management of chronic myeloid leukemia

    Article • Future Oncology, January 2020, Future Medicine

    Dr Ahmet Emre Eskazan

  87. Replacing chemotherapy with arsenic trioxide for the treatment of acute promyelocytic leukemia in the frontline setting: Is it cost‐effective?

    Article • Cancer, November 2019, Wiley

    Dr Ahmet Emre Eskazan

  88. The Impact and Prognostic Significance of Chronic Lymphocytic Leukemia Upregulated 1 (CLLU1) Gene Expression in Patients with Chronic Lymphocytic Leukemia: A Single Center Experience

    Article • Laboratory Medicine, September 2019, Oxford University Press (OUP)

    Dr Ahmet Emre Eskazan, Dr Mustafa Sevinc

  89. New drugs approved for acute myeloid leukemia (AML) in 2018

    Article • British Journal of Clinical Pharmacology, August 2019, Wiley

    Dr Ahmet Emre Eskazan

  90. Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia

    Article • Oncology and Therapy, August 2019, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  91. Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukemia are associated with hematologic toxicities – which TKI is the safest?

    Article • British Journal of Clinical Pharmacology, August 2019, Wiley

    Dr Ahmet Emre Eskazan

  92. The tolerability issue of generic imatinib in patients with chronic myeloid leukemia (Comment on Adi J. Klil-Drori et al., Haematologica 2019;104(7):e293)

    Article • Haematologica, June 2019, Ferrata Storti Foundation (Haematologica)

    Dr Ahmet Emre Eskazan

  93. An alternative way – tyrosine kinase inhibitor (TKI) de-escalation – to discontinue TKIs in order to achieve treatment-free remission

    Article • Expert Review of Hematology, June 2019, Taylor & Francis

    Dr Ahmet Emre Eskazan, ahmad kunbaz

  94. The outcomes of chronic myeloid leukemia patients with molecular warning responses under imatinib according to the European LeukemiaNet (ELN) 2013 recommendations

    Article • Clinical Lymphoma Myeloma & Leukemia, April 2019, Elsevier

    Dr Ahmet Emre Eskazan

  95. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura

    Article • Drug Design Development and Therapy, April 2019, Dove Medical Press

    Dr Ahmet Emre Eskazan

  96. Is measuring plasma imatinib trough levels still an appropriate way for predicting responses in patients with chronic myeloid leukemia?

    Article • Leukemia & Lymphoma, February 2019, Taylor & Francis

    Dr Ahmet Emre Eskazan

  97. Coexistence of Hermansky-Pudlak syndrome and JAK2V617F-positive essential thrombocythemia

    Article • Ultrastructural Pathology, January 2019, Taylor & Francis

    Dr Ahmet Emre Eskazan, Muhlis Cem Ar, BASAK ISILDAR

  98. Tyrosine Kinase Inhibitor–Associated Platelet Dysfunction: Does This Need to Have a Significant Clinical Impact?

    Article • Clinical and Applied Thrombosis/Hemostasis, January 2019, SAGE Publications

    Dr Ahmet Emre Eskazan

  99. Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?

    Article • Cancer, October 2018, Wiley

    Dr Ahmet Emre Eskazan

  100. Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?

    Article • Leukemia Research, September 2018, Elsevier

    Dr Ahmet Emre Eskazan

  101. Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword

    Article • Acta Oncologica, August 2018, Taylor & Francis

    Dr Ahmet Emre Eskazan

  102. Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors

    Article • Leukemia & Lymphoma, July 2018, Taylor & Francis

    Dr Ahmet Emre Eskazan, Muhlis Cem Ar

  103. Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single Institution Experience

    Article • Balkan Medical Journal, July 2018, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  104. Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?

    Article • British Journal of Clinical Pharmacology, June 2018, Wiley

    Dr Ahmet Emre Eskazan

  105. The issue of financial toxicity in the management of chronic myeloid leukemia with blast crisis

    Article • Journal of Medical Economics, May 2018, Taylor & Francis

    Dr Ahmet Emre Eskazan

  106. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia

    Article • Cancer, April 2018, Wiley

    Dr Ahmet Emre Eskazan

  107. Dasatinib-Induced Pulmonary Arterial Hypertension

    Article • British Journal of Clinical Pharmacology, January 2018, Wiley

    Dr Ahmet Emre Eskazan

  108. Cytopenia in adult brucellosis patients

    Article • International Journal of Microbiology Research, January 2018, Medknow

    Dr Ahmet Emre Eskazan

  109. Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience

    Article • Turkish Journal of Hematology, December 2017, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  110. Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib

    Article • International Journal of Clinical Oncology, November 2017, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  111. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, November 2017, New England Journal of Medicine (NEJM/MMS)

    Dr Ahmet Emre Eskazan

  112. Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature

    Article • Hematology, October 2017, Taylor & Francis

    Dr Ahmet Emre Eskazan

  113. Retrospective evaluation of hairy cell leukemia patients treated with 3 different first-line treatment modalities in the last two decades: a single center experience

    Article • Turkish Journal of Hematology, September 2017, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  114. Outcome of Chronic Myeloid Leukemia Patients with Early Molecular Response at 3 and 6 months: a Comparative Analysis of Generic Imatinib and Glivec

    Article • Clinical Lymphoma Myeloma & Leukemia, August 2017, Elsevier

    Dr Ahmet Emre Eskazan

  115. Vascular adverse events under long-term nilotinib therapy in patients with chronic myeloid leukemia

    Article • Clinical Lymphoma Myeloma & Leukemia, August 2017, Elsevier

    Dr Ahmet Emre Eskazan

  116. Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update

    Article • Therapeutic Advances in Hematology, July 2017, SAGE Publications

    Dr Ahmet Emre Eskazan

  117. Comment and response to: the significance of early warning in chronic myeloid leukemia

    Article • Expert Review of Hematology, June 2017, Taylor & Francis

    Dr Ahmet Emre Eskazan

  118. Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events – is better always good?

    Article • Expert Review of Hematology, June 2017, Taylor & Francis

    Dr Ahmet Emre Eskazan

  119. Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed-Refractory to IMiDs and Proteasome Inhibitors

    Article • Turkish Journal of Hematology, March 2017, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  120. Additional chromosomal abnormalities at diagnosis or during tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

    Article • Leukemia & Lymphoma, February 2017, Taylor & Francis

    Dr Ahmet Emre Eskazan

  121. Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase

    Article • Expert Opinion on Pharmacotherapy, January 2017, Taylor & Francis

    Dr Ahmet Emre Eskazan

  122. Do all patients with chronic myeloid leukemia need to receive interferon during pregnancy?

    Article • Leukemia & Lymphoma, January 2017, Taylor & Francis

    Dr Ahmet Emre Eskazan

  123. Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations

    Article • Drug Design Development and Therapy, October 2016, Dove Medical Press

    Dr Ahmet Emre Eskazan

  124. Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura

    Article • Annals of Hematology, September 2016, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  125. Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting

    Article • European Journal of Clinical Pharmacology, August 2016, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  126. Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in a Developing Country

    Article • Clinical Therapeutics, March 2016, Elsevier

    Dr Ahmet Emre Eskazan

  127. Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia

    Article • Journal of Clinical Pathology, January 2016, BMJ

    Dr Ahmet Emre Eskazan

  128. Pleural tuberculosis in a patient with untreated type 1 Gaucher disease

    Article • Journal of Infection and Chemotherapy, January 2016, Elsevier

    Dr Ahmet Emre Eskazan

  129. Comparison of International Prognostic Index and NCCN-IPI in 324 patients withde novodiffuse large B-cell lymphoma: a multi-center retrospective analysis

    Article • Leukemia & Lymphoma, October 2015, Taylor & Francis

    Dr Ahmet Emre Eskazan

  130. Congenital Dyserythropoietic Anemia Type 1: Report of One Patient and Analysis of Previously Reported Patients Treated with Interferon Alpha

    Article • Indian Journal of Hematology and Blood Transfusion, September 2015, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  131. Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy

    Article • The Turkish Journal of Gastroenterology, April 2015, AVES Publishing Co.

    Dr Ahmet Emre Eskazan

  132. Relapse after allogeneic hematopoietic stem cell transplant in patients with chronic myeloid leukemia: tyrosine kinase inhibitors, donor lymphocyte infusions or both?

    Article • Leukemia & Lymphoma, March 2015, Taylor & Francis

    Dr Ahmet Emre Eskazan

  133. Generic imatinib in the treatment of chronic myeloid leukemia: Cerrahpaşa experience

    Article • Journal of Oncology Pharmacy Practice, February 2015, SAGE Publications

    Dr Ahmet Emre Eskazan

  134. Treatment and Outcome of Primary and Secondary Thrombotic Microangiopathies

    Article • American Journal of Nephrology, January 2015, Karger Publishers

    Dr Ahmet Emre Eskazan

  135. Second primary malignancies in chronic myeloid leukemia patients

    Article • Journal of Cancer Research and Therapeutics, January 2015, Medknow

    Dr Ahmet Emre Eskazan

  136. Radotinib in the treatment of chronic phase chronic myeloid leukemia patients

    Article • Haematologica, December 2014, Ferrata Storti Foundation (Haematologica)

    Dr Ahmet Emre Eskazan

  137. Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options

    Article • Turkish Journal of Hematology, December 2014, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  138. The current situation and future aspects of cost-effectiveness in chronic myeloid leukemia treatment

    Article • Leukemia & Lymphoma, November 2014, Taylor & Francis

    Dr Ahmet Emre Eskazan

  139. Spondylodiscitis: evaluation of patients in a tertiary hospital

    Article • The Journal of Infection in Developing Countries, October 2014, Journal of Infection in Developing Countries

    Dr Ahmet Emre Eskazan, Serdar Ercan

  140. Generics in chronic myeloid leukemia: current arguments for and against and the established evidence

    Article • Expert Review of Hematology, October 2014, Taylor & Francis

    Dr Ahmet Emre Eskazan

  141. The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient safety?

    Article • Leukemia & Lymphoma, August 2014, Taylor & Francis

    Dr Ahmet Emre Eskazan

  142. Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion

    Article • Leukemia Research, July 2014, Elsevier

    Dr Ahmet Emre Eskazan

  143. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate

    Article • British Journal of Haematology, May 2014, Wiley

    Dr Ahmet Emre Eskazan

  144. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia

    Article • Leukemia & Lymphoma, May 2014, Taylor & Francis

    Dr Ahmet Emre Eskazan

  145. The Role of Nitric Oxide in Doxorubicin-Induced Cardiotoxicity: Experimental Study

    Article • Turkish Journal of Hematology, March 2014, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  146. Bone marrow transplantation for Behcet's disease: a case report and systematic review of the literature

    Article • Rheumatology, February 2014, Oxford University Press (OUP)

    Dr Ahmet Emre Eskazan

  147. Two Cases of Autoimmune Hemolytic Anemia Secondary to Brucellosis: A Review of Hemolytic Disorders in Patients with Brucellosis

    Article • Internal Medicine, January 2014, Japanese Society of Internal Medicine

    Dr Ahmet Emre Eskazan

  148. Postoperative thrombotic thrombocytopenic purpura

    Article • Surgery Today, December 2013, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  149. Brucellar pericarditis: a report of four cases and review of the literature

    Article • International Journal of Infectious Diseases, June 2013, Elsevier

    Dr Ahmet Emre Eskazan

  150. B-Cell Chronic Lymphocytic Leukemia and Colon Adenocarcinoma in the Same Mesenteric Lymph Node

    Article • Turkish Journal of Hematology, March 2013, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  151. Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia

    Article • Turkish Journal of Hematology, February 2013, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  152. Diagnostic dilemma: metastatic bone malignancy or primary hyperparathyroidism with brown tumor

    Article • Open Journal of Internal Medicine, January 2013, Scientific Research Publishing, Inc,

    Dr Ahmet Emre Eskazan

  153. Interstitial Pneumonitis in a Patient with Chronic Myeloid Leukemia

    Article • Turkish Journal of Hematology, January 2013, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  154. Acute Acalculous Cholecystitis due to Viral Hepatitis A

    Article • Case Reports in Infectious Diseases, January 2013, Hindawi Publishing Corporation

    Dr Ahmet Emre Eskazan

  155. Interstitial Pneumonitis in a Patient with Chronic Myeloid Leukemia

    Article • Turkish Journal of Hematology, January 2013, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  156. Detailed Analysis of Diffuse Large B Cell Lymphoma Patients: A Single-Center, Retrospective Study

    Article • ISRN Hematology, January 2013, Hindawi Publishing Corporation

    Dr Ahmet Emre Eskazan

  157. Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients

    Article • Turkish Journal of Hematology, January 2013, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  158. Breast schwannoma in a patient with diffuse large B-cell lymphoma: a case report

    Article • Journal of Medical Case Reports, December 2012, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  159. Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature

    Article • Transfusion, November 2012, Wiley

    Dr Ahmet Emre Eskazan

  160. Successful Management of Chronic Refractory Immune Thrombocytopenia with Laparoscopic Splenectomy in a Patient with Acute Promyelocytic Leukemia

    Article • Indian Journal of Hematology and Blood Transfusion, July 2012, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  161. Intracranial extramedullary hematopoiesis in patients with thalassemia: a case report and review of the literature

    Article • Transfusion, January 2012, Wiley

    Dr Ahmet Emre Eskazan

  162. Hypereosinophilic Syndrome Associated with Simultaneous Intracardiac Thrombi, Cerebral Thromboembolism and Pulmonary Embolism

    Article • Internal Medicine, January 2012, Japanese Society of Internal Medicine

    Dr Ahmet Emre Eskazan

  163. The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

    Article • Turkish Journal of Hematology, January 2012, LookUs Bilisim, Ltd.

    Dr Ahmet Emre Eskazan

  164. Essential Thrombocythemia and Multiple Myeloma: Two Rare Diseases in One Patient

    Article • Clinical Lymphoma Myeloma & Leukemia, October 2011, Elsevier

    Dr Ahmet Emre Eskazan

  165. Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?

    Article • Leukemia Research, September 2011, Elsevier

    Dr Ahmet Emre Eskazan

  166. Thrombotic Thrombocytopenic Purpura After Prophylactic Cefuroxime Axetil Administered in Relation to a Liposuction Procedure

    Article • Aesthetic Plastic Surgery, August 2011, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  167. Variant Philadelphia translocations with different breakpoints in six chronic myeloid leukemia patients

    Article • Turkish Journal of Hematology, August 2011, LookUs Bilisim, Ltd.

    Dr Ahmet Emre Eskazan

  168. ABL gene kinase domain mutation scanning by denaturing high performance liquid chromatography sequencing method

    Article • Turkish Journal of Hematology, June 2011, LookUs Bilisim, Ltd.

    Dr Ahmet Emre Eskazan

  169. Chronic lymphocytic leukemia developing in a patient with Janus kinase 2 V617F mutation positive myeloproliferative neoplasm

    Article • Annals of Hematology, May 2011, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  170. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy

    Article • Haematologica, February 2011, Ferrata Storti Foundation (Haematologica)

    Dr Ahmet Emre Eskazan

  171. Primary Gastrointestinal Diffuse Large B Cell Lymphoma Presenting with Cold Agglutinin Disease

    Article • Case Reports in Gastroenterology, January 2011, Karger Publishers

    Dr Ahmet Emre Eskazan

  172. Synchronous Detection of Hairy Cell Leukemia and HIV-Negative Kaposi’s Sarcoma of the Lymph Node: A Diagnostic Challenge and a Rare Coincidence

    Article • Case Reports in Oncology, January 2011, Karger Publishers

    Dr Ahmet Emre Eskazan

  173. Intracranial mass in a patient with thalassaemia major

    Article • British Journal of Haematology, November 2010, Wiley

    Dr Ahmet Emre Eskazan

  174. Sarcoidosis mimicking lymphoma on positron emission tomography-computed tomography in two patients treated for lymphoma: two case reports

    Article • Journal of Medical Case Reports, January 2009, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  175. Cytogenetic Clonal Evolution in Patients with Chronic Myeloid Leukemia

    Article • Biotechnology & Biotechnological Equipment, January 2009, Taylor & Francis

    Dr Ahmet Emre Eskazan

  176. Primary Cutaneous Immunocytoma/Marginal Zone B-Cell Lymphoma: A Case with Unusual Course

    Article • American Journal of Dermatopathology, April 2004, Wolters Kluwer Health

    Dr Ahmet Emre Eskazan